Nanology.us – Advancing Tumor-Directed Drug Therapy
  • About
    • Overview
    • Team & Advisors
    • Partnering Opportunities
  • Technology
  • Development
    • Products
    • Pipeline
    • Clinical Programs
    • Immunogenic Effect
    • Partnering Opportunities
  • News & Publications
  • Contact
    • Partnering Opportunities
    • Physicians and Patients
logo

Archive for the Home Page Category

BIOCEO19 Video: Reshaping Tumor Microenvironments via Immunotherapies. Panel including Gere diZerega, MD, Chief Medical Officer of NanOlogy

On February 24, 2019   /   Home Page, Presentations  
BIOCEO19 Video: Reshaping Tumor Microenvironments via Immunotherapies. Panel including Gere diZerega, MD, Chief Medical Officer of NanOlogy

 

Back to Top

ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

On February 19, 2019   /   Home Page, Presentations  
ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

Back to Top

NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019

On January 11, 2019   /   Home Page, NanOlogy in the News  
NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019
Back to Top

Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy

On November 6, 2018   /   Home Page, NanOlogy in the News  
Wuxi  AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
Back to Top
Page 2 of 2«12

Recent Nanology News

  • NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer March 7, 2023
  • NanOlogy General Presentation (January 2023) January 6, 2023
  • NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts December 20, 2022
  • Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cysts December 15, 2022
  • NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer November 11, 2022

Home
About
Technology
Development
News & Publications
Contact

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.

© 2017-23 NanOlogy LLC     Legal
Back to Top
This website uses cookies to improve your experience. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit the Cookie Settings to provide a controlled consent. Cookie settings ACCEPT
Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

This is an necessary category.

Non Necessary

This is an non-necessary category.

Save & Accept